Search results
Results from the WOW.Com Content Network
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. [10] [11] [8] It is taken by mouth. [10] [8] Common side effects include headache, constipation, sleepiness, and dizziness. [10] [11] Severe side effects may include blood clots, psychosis, and heart ...
Ebastine is a H 1 antihistamine with low potential for causing drowsiness.. It does not penetrate the blood–brain barrier to a significant amount and thus combines an effective block of the H 1 receptor in peripheral tissue with a low incidence of central side effects, i.e. seldom causing sedation or drowsiness.
Bilastine is an antihistamine medication used to treat hives (), allergic rhinitis and itchy inflamed eyes (allergic conjunctivitis) caused by an allergy. [6] It is a second-generation antihistamine and takes effect by selectively inhibiting the histamine H 1 receptor, preventing these allergic reactions. [7]
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. [5] It is prescribed for nausea and vomiting due to motion sickness [6] or other sources such as chemotherapy, [7] vertigo, [8] or Ménière's disease. [9]
Galantamine is a type of acetylcholinesterase inhibitor.It is an alkaloid extracted from the bulbs and flowers of Galanthus nivalis (common snowdrop), Galanthus caucasicus (Caucasian snowdrop), Galanthus woronowii (Voronov's snowdrop), and other members of the family Amaryllidaceae, such as Narcissus (), Leucojum aestivum (snowflake), and Lycoris including Lycoris radiata (red spider lily). [5]
Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.
Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials. [1] [7] [8] Aside from Alzheimer's disease, there are other amyloid beta related diseases, in which solanezumab could be used, e.g., Down syndrome or cerebral amyloid angiopathy. [9]
In a large clinical trial of the rivastigmine patch in 1,195 patients with Alzheimer's disease, the target dose of 9.5 mg/24-hour patch provided similar clinical effects (e.g. memory and thinking, activities of daily living, concentration) as the highest doses of rivastigmine capsules, but with one-third fewer reports of nausea and vomiting. [8]